DK2435583T3 - miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI - Google Patents
miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFIInfo
- Publication number
- DK2435583T3 DK2435583T3 DK10723982T DK10723982T DK2435583T3 DK 2435583 T3 DK2435583 T3 DK 2435583T3 DK 10723982 T DK10723982 T DK 10723982T DK 10723982 T DK10723982 T DK 10723982T DK 2435583 T3 DK2435583 T3 DK 2435583T3
- Authority
- DK
- Denmark
- Prior art keywords
- duchennes
- mir
- treatment
- muscle
- drops
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20090161038 EP2258863A1 (en) | 2009-05-25 | 2009-05-25 | miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics |
PCT/EP2010/057093 WO2010136417A1 (en) | 2009-05-25 | 2010-05-24 | miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2435583T3 true DK2435583T3 (da) | 2014-09-29 |
Family
ID=40718989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10723982T DK2435583T3 (da) | 2009-05-25 | 2010-05-24 | miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI |
Country Status (4)
Country | Link |
---|---|
US (1) | US9034838B2 (da) |
EP (1) | EP2435583B1 (da) |
DK (1) | DK2435583T3 (da) |
WO (1) | WO2010136417A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2206781B1 (en) | 2004-06-28 | 2015-12-02 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
SI3133160T1 (sl) | 2008-10-24 | 2019-05-31 | Sarepta Therapeutics, Inc. | Sestavki, ki preskakujejo ekson za DMD |
ES2693459T3 (es) | 2009-11-12 | 2018-12-11 | The University Of Western Australia | Moléculas antisentido y métodos para el tratamiento de patologías |
EP2535412A1 (en) * | 2011-06-17 | 2012-12-19 | Universitat Pompeu-Fabra | New treatment for muscular dystrophies |
EP3633035A1 (en) | 2013-03-14 | 2020-04-08 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
BR112015022998A2 (pt) | 2013-03-15 | 2017-11-14 | Sarepta Therapeutics Inc | composições melhoradas para o tratamento de distrofia muscular |
US9637738B2 (en) | 2013-04-10 | 2017-05-02 | Reveragen Biopharma, Inc. | Methods and agents to increase therapeutic dystrophin expression in muscle |
EP3598978B1 (en) | 2018-07-26 | 2024-05-29 | EXOFIX S.r.l. | Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles |
EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
ES2534304T3 (es) | 2004-11-12 | 2015-04-21 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
US20100202973A1 (en) | 2007-05-18 | 2010-08-12 | Karolinska Institutet Innovations Ab | Microrna molecules associated with inflammatory skin disorders |
-
2010
- 2010-05-24 US US13/322,023 patent/US9034838B2/en not_active Expired - Fee Related
- 2010-05-24 EP EP20100723982 patent/EP2435583B1/en not_active Not-in-force
- 2010-05-24 DK DK10723982T patent/DK2435583T3/da active
- 2010-05-24 WO PCT/EP2010/057093 patent/WO2010136417A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010136417A1 (en) | 2010-12-02 |
EP2435583A1 (en) | 2012-04-04 |
US9034838B2 (en) | 2015-05-19 |
EP2435583B1 (en) | 2014-07-09 |
US20120129920A1 (en) | 2012-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2435583T3 (da) | miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI | |
DK2448637T4 (da) | Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi | |
HK1225316A1 (zh) | 治療病毒感染的方法 | |
BRPI1010197A2 (pt) | métodos e compostos de pirazolopirimidina jak | |
IL208354A0 (en) | Methods of treatment | |
DK2329012T3 (da) | Behandling af slagtilfælde under anvendelse af isolerede placentaceller | |
DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
EP2254597A4 (en) | TREATMENT PROCEDURE WITH ANTI-MIF ANTIBODIES | |
DK2498771T3 (da) | Anvendelse af bethanechol til behandling af xerostomi | |
DK2350116T3 (da) | Behandling af biofilm | |
DK3124610T3 (da) | Hbv-behandling | |
DK2373927T3 (da) | Behandling af forbrændingsgas fra affaldsbehandling | |
BRPI0919127A2 (pt) | métodos para tratamento de água | |
DK2382232T3 (da) | Fremgangsmåde til fremstilling af bivalirudin | |
BR112014015551A8 (pt) | método para tratar lama e método para desidratação de lama | |
BRPI0916079A2 (pt) | tratamento de água marinha residual | |
DK2554171T3 (da) | Fremgangsmåde til behandling af sygdomme | |
DK2501381T3 (da) | Behandling af atrieflimmer | |
DK2297047T3 (da) | Indretning til rensning af spildevand | |
EP2164494A4 (en) | Methods of Treatment | |
DK2229943T3 (da) | Forbindelse til anvendelse ved behandling af perifer neuropati | |
FI20090395A0 (fi) | Kompostipuhdistamo | |
EP2349299A4 (en) | COMPOSITION FOR THE TREATMENT OF HYPERTENSION | |
EP2440238A4 (en) | Methods of Treatment | |
ES1070372Y (es) | Rifle monotiro desmontable y mejorado |